Scientists Study P300 and CBP Inhibitors for Disease
Researchers are investigating new chemical inhibitors to potentially treat cancers, metabolic disorders, and other conditions.
Updated on Oct. 30, 2026 in Biotech
Scientists are exploring the potential of p300/CBP inhibitors as a new therapeutic approach for targeting cancers, inflammatory diseases, and neurodegenerative conditions. These transcriptional coactivators are essential biological targets, though current research remains strictly in the preclinical stage.
Why it matters
Developing these inhibitors is challenging due to the high functional homology between p300 and CBP proteins, which complicates the creation of highly selective drugs. Successfully managing off-target effects remains a critical hurdle for moving these treatments into human clinical trials.
Current research tools for HAT inhibition include C646, A-485, and CPTH2, while SGC-CBP30 and I-CBP112 target bromodomain interactions. These compounds serve as foundational models for modulating transcriptional activity in laboratory environments.
The players
p300/CBP
These transcriptional coactivators play a vital role in gene regulation and possess histone acetyltransferase activity.
The details
Research strategies focus on inhibiting either the histone acetyltransferase activity or the bromodomain interactions of these proteins. Scientists are also evaluating potential combination therapies that pair these inhibitors with existing chemotherapies or other epigenetic modulators.
Timeline
2026: The year of this scientific overview.
The Tech Race
This research follows the developmental path established by the BET bromodomain inhibitor JQ1 in the broader field of epigenetic modulation. The quest to control p300/CBP represents a shift toward more complex, targeted transcriptional regulation within biotechnology.
Because these inhibitors are currently in the preclinical stage, they do not yet offer immediate treatment options for patients or changes to standard clinical care. The research focus remains on establishing the feasibility of these compounds for future medicinal use.
The takeaway
The development of selective p300/CBP inhibitors offers a promising long-term strategy for precision medicine. Researchers must first overcome the technical challenges of protein selectivity before these tools can progress toward clinical application.
Further reading
Learn more about the latest developments in Biotech.
Source note: This article includes information reported by Alwasat-ye.
